Posted from: Tuesday, March 20, 2018 - 03:34 PM - Present

Cosentyx Receives Expanded Indication

February 8, 2018 – The U.S. FDA has approved an expanded indication for Cosentyx® (secukinumab), manufactured by Novartis. The drug is now approved to treat moderate-to-severe scalp psoriasis. Previously, Cosentyx’s FDA-approved use in the treatment of psoriasis was restricted to moderate-to-severe plaque psoriasis.

Scalp psoriasis is considered one of the more difficult forms of psoriasis to treat. It affects approximately half of all psoriasis patients; approximately 4 million psoriasis patients in the U.S. have scalp psoriasis, according to the National Psoriasis Foundation. The expanded indication for Cosentyx to treat the condition is based on a clinical study in which it demonstrated favorable safety and efficacy profiles compared to placebo.

Recommended dosing is based on indication and on individual patient needs. Cosentyx is administered via subcutaneous injection. Originally approved in 2015 to treat psoriasis, it is also indicated to treat ankylosing spondylitis and psoriatic arthritis.

 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Monday, October 15, 2018 - 11:03 PM.